Spinraza's Second Act: How a Higher Dose Could Save Biogen's Biggest Franchise

For context, a meaningful improvement on this scale can mean the difference between a baby who can hold up their head and one who can't.

Older patients who switched from the standard dose also showed gains: an average 1.8-point increase on a different motor scale (HFMSE) and 1.2 points on an upper limb function test. Those numbers sound modest, but in a disease where stability counts as a win, any upward movement is noteworthy.

The Biomarker Story Is Just as Interesting

Beyond what patients could physically do, the trial tracked something happening at the molecular level. Neurofilament proteins leak into the blood when nerve cells are dying. They're essentially a smoke alarm for neurodegeneration.

The high-dose regimen reduced neurofilament levels faster than the standard dose. This matters because it suggests the drug isn't just improving symptoms; it's slowing the underlying damage more aggressively. For a disease that progressively destroys motor neurons, buying time at the cellular level could translate into years of preserved function.

Safety? The high-dose regimen looked comparable to the standard one. Adverse events were consistent across both groups, with no new red flags in clinical or lab measures.

A Rocky Road to Approval

This approval didn't come easy. In September 2025, the FDA sent Biogen a Complete Response Letter (CRL), which is the regulatory equivalent of "nice try, but fix this first." The rejection wasn't about whether the drug worked or was safe. It was about manufacturing issues (known in regulatory circles as CMC problems).

That CRL was a gut punch. The rejection delayed the U.S. launch and sent an already nervous investor base further into doubt.

Biogen had already secured approval in the European Union, so the drug was reaching patients overseas. But the U.S. market is the prize, and the resubmission timeline of 9 to 18 months loomed large. In the end, Biogen resolved the manufacturing concerns faster than many expected, clearing the way for the late March 2026 approval.

Why This Matters Beyond Biogen

The SMA treatment landscape is getting crowded, and that's actually great news for patients. Novartis now has Itvisma, an intrathecal gene therapy (injected into the spinal fluid) approved for patients over two years old. Evrysdi remains the easiest option: it's a liquid you take at home. And newer challengers are lining up, including Scholar Rock's apitegromab (which attacks the disease through a completely different mechanism) and salanersen, a next-gen therapy that could offer once-yearly dosing.

But the high-dose Spinraza approval does something broader for the industry. It validates dose optimization as a competitive strategy. Rather than inventing a new drug, Biogen proved you can squeeze more efficacy out of an existing one by giving more of it. It's a playbook that other companies with aging genetic medicines will be watching closely.

The FDA's Project Optimus initiative, launched in 2021, has been pushing drugmakers to figure out optimal dosing earlier in development rather than just defaulting to the maximum tolerated dose. Biogen's high-dose Spinraza is, in a way, the flip side of that coin: going back to prove that the original dose wasn't enough.

The Bottom Line

Spinraza was losing a three-way fight for SMA patients. Its competitors offered convenience (a liquid taken at home) and simplicity (a one-time infusion). Biogen's answer was to make its drug work harder, not differently.

Whether that's enough to reverse years of revenue erosion remains an open question. The franchise needs to convince doctors and patients that a more potent spinal injection justifies the hassle over Evrysdi's oral simplicity or Zolgensma's one-and-done promise. But with the broadest label in its history and clinical data showing clear improvements over the original dose, Spinraza just gave itself a real shot at a second act.

The Muscular Dystrophy Association called it a milestone built on decades of research. For the roughly 10,000 to 25,000 people living with SMA in the U.S., it's something simpler: another option, and a better one than before.

The UK Just Got a Hall Pass From America's Pharma Tariff Apocalypse

The UK just became the only country with tariff-free pharmaceutical access to the U.S. market, dodging 100% duties that everyone else still faces. The price? A 25% hike in what the NHS pays for new drugs, and a template that could reshape global pharma negotiations.